The lived experience of Australian opioid replacement therapy recipients in a community-based program in regional Victoria.
consumer perceptions
opiate substitution therapy
opioid replacement therapy
pharmacotherapy in regional Victoria
qualitative research
Journal
Drug and alcohol review
ISSN: 1465-3362
Titre abrégé: Drug Alcohol Rev
Pays: Australia
ID NLM: 9015440
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
received:
27
01
2019
revised:
31
07
2019
accepted:
01
08
2019
entrez:
3
10
2019
pubmed:
3
10
2019
medline:
18
3
2020
Statut:
ppublish
Résumé
Treatment of opioid dependence through opioid replacement therapy is widely recognised as effective. Nonetheless, while there has been a community-based program in the state of Victoria for over two decades, consumer experiences have received little attention. This study aimed to describe the experiences of opioid replacement therapy consumers living in rural and regional areas of the state. A qualitative design employed an interpretative phenomenological approach. Sixteen consumers were interviewed. Thematic analysis was conducted by the researchers to examine the phenomena of consumers' experiences and findings were verified by a stakeholder group. Findings centred on themes of consumers' experience of becoming recipients; consumer perceptions of pharmacists and pharmacy settings and psychosocial impacts on consumers. A majority of participants believed opioid replacement therapy brought increased normality to their life, however systemic and psychosocial barriers impacted on well-being. The pharmacy setting itself as a public dosing space commonly provoked feelings of stigma and discrimination among consumers. Other barriers prominently reported were restrictions on number of takeaways, cost of dispensing and lack of access to medical practitioners and allied supports. There were psychosocial impacts on opioid replacement therapy consumers relating to financial and social burdens, stigma and discrimination. Access to medical care and a choice of pharmacy appeared to be restricted in rural regions. The findings suggest a need to address, in particular, the financial and dispensing point burdens experienced by consumers to facilitate program retention.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
656-663Informations de copyright
© 2019 Australasian Professional Society on Alcohol and other Drugs.
Références
Soyka M, Strehle J, Rehm J, Bühringer G, Wittchen H-U. Six-year outcome of opioid maintenance treatment in heroin-dependent patients: results from a naturalistic study in a nationally representative sample. Eur Addict Res 2017;23:97-105.
Degenhardt LF, Charlson B, Mathers WD et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction 2014;09:1320-33.
Peacock A, Leung J, Larney S et al. Global statistics on alcohol, tobacco and illicit drug use: 2017 status report. Addiction 2018;113:1905-26.
Weiss RD, Potter JS, Griffin ML et al. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment study. Drug Alcohol Depend 2015;150:112-9.
Degenhardt LC, Bucello B, Mathers C et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011;106:32-51.
Degenhardt L, Randall D, Hall W, Law M, Butle T, Burns L. Mortality among clients of a state wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009;105:9-15.
Gowing L, Ali R, Dunlop A, Farrell M Lintzeris N. National guidelines for medication-assisted treatment of opioid dependence. Canberra, Commonwealth of Australia, 2014;38-9
Department of Health, Victoria. Policy for maintenance pharmacotherapy for opioid dependence. Melbourne, VIC: State of Victoria Department of Health, 2013 Available at: http://docs2.health.vic.gov.au/docs/doc/F41321F8CFC269C6CA257B0400075C1B/$FILE/Pharmacotherapy%20Policy%202013-v02.pdf (accessed July 2017).
Burns L, Gisev N, Larney S et al. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. Addiction 2015;110:646-55.
Guan Q, Khuu W, Spithoff S et al. Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014. Drug Alcohol Depend 2017;177:315-21.
Oretti R. A retrospective evaluation of inpatient transfer from high-dose methadone to buprenorphine substitution therapy. J Subs Abuse Treat 2015;57:102-5.
Gisev N, Shanahan M, Weatherburn DJ et al. A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. Addiction 2015;110:1975-84.
Lea P, Hotham ED. South Australian rural community pharmacists and the provision of methadone, buprenorphine and injecting equipment. Int J Pharm Pract 2008;16:149-54.
Lea T, Sheridan J, Winstock A. Consumer satisfaction with opioid treatment services at community pharmacies in Australia. Pharm World Sci 2008;30:940-6.
Burns L, Randall D, Hall WD et al. Opioid agonist pharmacotherapy in New South Wales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction 2009;104:1363-72.
Patil Vishwanath T, Cash P, Penney W. A narrative review of pharmacotherapy treatment for opioid addiction and application in a community-based model in Victoria, Australia. Int J Ment Heal Addict 2018;14:72.
Shepherd A, Perrella B, Hattingh HL. The impact of dispensing fees on compliance with opioid substitution therapy: a mixed methods study. Subs Abuse Treat Prevent Policy 2014;9:32.
Fraser S. The chronotope of the queue: methadone maintenance treatment and the production of time, space and subjects. Int J Drug Policy 2006;17:192-202.
Crawford S. Shouting through bullet-proof glass: some reflections on pharmacotherapy provision in one Australian clinic. Int J Drug Policy 2013;24:e14-7.
Mackey S. Phenomenological nursing research: methodological insights derived from Heidegger′s interpretive phenomenology. Int J Nurs Stud 2004;42:179-86.
Connelly LM. What is phenomenology. Med Surg Nurs 2010;19:127-8.
Schneider Z, Whitehead D, Elliot D. Nursing and midwifery research- methods and appraisal for evidence-based practice, 3rd edn. Sydney, Australia: Elsevier, 2008.
Kelly S. Qualitative interviewing techniques and styles. In: Bourgeault I, Dingwall R, De Vries R, eds. The sage handbook of qualitative methods in health research. London: Sage Publications, 2010.
Kumar R. Research methodology: a step-by-step guide for beginners. London: Sage Publishing Ltd, 2010.
Pope C, Ziebland S, Mays N. Analysing qualitative data. Qualitative research in health care. BMJ 2006;3:63-81.
Chalmers J, Ritter A. Subsidising patient dispensing fees: the cost of injecting equity into the opioid pharmacotherapy maintenance system. Drug Alcohol Rev 2012;31:911-7.
Rowe J. A raw deal. Melbourne, VIC: RMIT University and the Salvation Army, 2008.
Penington Institute. Chronic unfairness: equal treatment for addiction medicines? Melbourne, VIC: Penington Institute, 2015 http://www.penington.org.au/wp-content/uploads/2015/04/Chronic-Unfairness-Penington-Institute.pdf.
McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010;19:4-16.
Kidorf M, King VL, Peirce J, Gandotra N, Ghazarian S, Brooner RK. Substance use and response to psychiatric treatment in methadone-treated outpatients with comorbid psychiatric disorder. J Sub Abuse Treat 2015;51:64-9.
Winstock AR, Lea T, Sheridan J. Patients′ help-seeking behaviours for health problems associated with methadone and buprenorphine treatment. Drug Alcohol Rev 2008;27:393-7.
Wright N, D′Agnone O, Krajci P et al. Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience. J Public Health 2016;38:e368-e74.
Tran BX, Bach XV, Phuong B et al. Drug addiction stigma in relation to methadone maintenance treatment by different service delivery models in Vietnam. BMC Public Health 2016;16:238.
Earnshaw V, Smith L, Copenhaver M. Drug addiction stigma in the context of methadone maintenance therapy: an investigation into understudied sources of stigma. Int J Ment Heal Addict 2013;11:110-22.
Lather P. Getting smart: feminist research and pedagogy with/in the postmodern. J Leis Res 1992;24:394.